MP5 Rec'd PCT/PTO 28 JUL 2006

Complete if Known IDS Form PTO/SB/08: Substitute for form 1449A/PTO Not Yet Assigned Application Number July 28, 2006 Filing Date INFORMATION DISCLOSURE First Named Inventor Shuichiro KAKIMOTO STATEMENT BY APPLICANT Not Yet Assigned Art Unit Examiner Name (Use as many sheets as necessary) Not Yet Assigned 03327.2354 Sheet Attorney Docket Number

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS							
Examiner Initials	Cite No.1	Document Number	Issue or	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Number-Kind Cade <sup>2</sup> (if known)	Publication Date MM-DD-YYYY		Relevant Passages or Relevant Figures Appear		
arh		US- 2003/0181421 A1	09-25-2003	HOROWITZ et al.			
are		US- 2002/0006441 A1	01-17-2002	GABEL et al.			
arm		US- 4,990,503	02-05-1991	ISOMURA et al.			
1		US-					

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
M		WO 00/38694	07-06-2000	YAMANOUCHI PHARMACEUTICAL CO., LTD.		Abstract
ne		WO 02/43738 A2	06-06-2002	NOVARTIS AG	·	
arh		JP 2003-137814	05-14-2003	TAKEDA CHEM IND LTD		Abstract
and		JP 2003-535889	12-02-2003			No
ay		JP 2002-527398	08-27-2002	F. HOFFMANN-LA ROCHE AG	-	No No
au,		JP 6-99457	12-07-1994			No
ar		WO 02/094767 A2	11-28-2002	ABBOTT LABORATORIES		
wh		JP 2003-238418	08-27-2003	INSPIRE PHARMACEUTICALS INC.		Abstract
Erl		WO 94/00462	01-06-1994	YAMANOUCHI PHARMACEUTICAL CO.		Abstract

NON PATENT LITERATURE DOCUMENTS					
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>			
	R. W. Sparidans, et al., "Bisphosphonates in bone diseases," Pharmacy World and Science, Vol. 20, No. 5, pp. 206-213, (1998).				
	A. Bonabello, et al., "Analgesic effect of bisphosphonates in mice," Pain, Vol. 91, pp. 269-275, (2001).				
	K. Walker, et al., "Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain," Pain, Vol. 100, pp. 219-229, (2002).				
		Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  R. W. Sparidans, et al., "Bisphosphonates in bone diseases," Pharmacy World and Science, Vol. 20, No. 5, pp. 206-213, (1998).  A. Bonabello, et al., "Analgesic effect of bisphosphonates in mice," Pain, Vol. 91, pp. 269-275, (2001).  K. Walker, et al., "Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a			

Examiner Signature	arhadien	Date Considered	08/01	12007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.